Related Experiment Video
Updated: Apr 18, 2026

Intracerebroventricular Delivery of Gut-Derived Microbial Metabolites in Freely Moving Mice
Published on: June 2, 2022
5-HT7 receptor signaling: improved therapeutic strategy in gut disorders
1Department of Pathology and Molecular Medicine, Farncombe Family Digestive Health Research Institute, McMaster University Hamilton, ON, Canada.
Abstract:
Serotonin (5-hydroxytryptamine; 5-HT) is most commonly known for its role as a neurotransmitter in the central nervous system (CNS). However, the majority of the body's 5-HT is produced in the gut by enterochromaffin (EC) cells. Alterations in 5-HT signaling have been associated with various gut disorders including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and enteric infections. Recently, our studies have identified a key role for 5-HT in the pathogenesis of experimental colitis. 5-HT7 receptors are expressed in the gut and very recently, we have shown evidence of 5-HT7 receptor expression on intestinal immune cells and demonstrated a key role for 5-HT7 receptors in generation of experimental colitis. This review summarizes the key findings of these studies and provides a comprehensive overview of our current knowledge of the 5-HT7 receptor in terms of its pathophysiological relevance and therapeutic potential in intestinal inflammatory conditions, such as IBD.
More Related Videos
Related Concept Videos
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Gut-Brain Axis
G-protein Coupled Receptors
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

